| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Cardiovascular Research Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226
Submitted 18 November 2002 ; accepted in final form 9 April 2003
 |
ABSTRACT |
|---|
 TOP ABSTRACT METHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
40% reduction) compared with the
control group (13.0 ± 3.2% vs. 25.2 ± 3.7% of the area at risk,
respectively). This effect of IB-MECA was blocked completely in dogs
pretreated with glibenclamide. An equivalent reduction in infarct size was
observed when IB-MECA was administered immediately before reperfusion (13.1
± 3.9%). These results are the first to demonstrate efficacy of an
A3AR agonist in a large animal model of myocardial infarction by
mechanisms that are unrelated to changes in hemodynamic parameters and
coronary blood flow. These data also demonstrate in an in vivo model that
IB-MECA is effective as a cardioprotective agent when administered at the time
of reperfusion.
heart; infarction
A3AR agonists such as N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide (IB-MECA) or N6-(3-chlorobenzyl)-adenosine-5'-N-methylcarboxamide (CB-MECA) and the 2-chloro derivative 2-Cl-IB-MECA have been shown to be effective cardioprotective agents in numerous in vitro and in vivo rodent models of ischemia-reperfusion injury (5, 9, 18, 19, 21, 22, 26, 33, 39–44). However, no studies have been performed with A3AR agonists in large animal models that have variable levels of collateral blood flow similar to that found in humans with coronary artery disease. The present study examined the effect of IB-MECA in an open-chest, anesthetized dog model of infarction.
|
METHODS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
Anesthetized dog model. A standard barbital-anesthetized dog model was employed, as described previously in detail (2, 4). All dogs were subjected to 60 min of left anterior descending (LAD) coronary artery occlusion and 3 h of reperfusion. Dogs were randomly assigned to one of four experimental groups: vehicle (1 ml solution of 50% DMSO in normal saline) given 10 min before coronary occlusion, IB-MECA (100 µg/kg iv bolus) given 10 min before coronary occlusion, IB-MECA (100 µg/kg iv bolus) given 5 min before reperfusion, and IB-MECA (100 µg/kg iv bolus) given 10 min before coronary occlusion with pretreatment 15 min earlier with the ATP-dependent potassium (KATP) channel antagonist glibenclamide (0.3 mg/kg iv bolus). Glibenclamide was administered at a dose that we have shown previously to have no effect on infarct size in our dog model (16). In all of the groups, hemodynamic measurements and arterial blood gases were obtained before occlusion, at 30 min of the 60-min occlusion period, and every hour after reperfusion. Regional myocardial blood flow was measured at 30 min during the 60-min occlusion period and at the end of the experiment. Throughout the ischemia-reperfusion experiments, heart rate was maintained at 150 beats/min by left atrial pacing. All procedures and protocols were approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin and complied with the procedures established by National Institutes of Health Guide for the Care and Use of Laboratory Animals.
After 3 h of reperfusion, the anatomic area at risk (AAR) and the nonischemic area were demarcated by staining with Evan's blue dye (2, 4). The hearts were electrically fibrillated, removed, and prepared for infarct size determination (using triphenyltetrazolium choride) and regional myocardial blood flow measurements (2, 4). Infarcted and noninfarcted tissues within the AAR were separated and determined gravimetrically. Regional myocardial blood flow was measured by the radioactive microsphere technique (2, 4). Dogs were excluded from the study if subendocardial collateral blood flow was >0.15 ml · min–1 · g–1 or if more than three consecutive attempts were required to convert ventricular fibrillation with low-energy direct current pulses.
Statistical analyses. All values are expressed as means ± SE. Hemodynamic variables were analyzed by two-way repeated-measures ANOVA (time and drug treatment) to determine whether there was a main effect of time, a main effect of treatment, or a time-treatment interaction. Infarct sizes and risk region sizes were compared using a one-way ANOVA, followed by Student's t-test with the Bonferroni correction.
|
RESULTS |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
50-fold selective at binding to the high-affinity form of the
A3AR versus the high-affinity form of the A1AR
(Fig. 1). The dissociation
constants were calculated to be 0.67 ± 0.09 and 33.8 ± 2.97 nM
for the A3AR and A1AR, respectively. In preliminary
studies, we examined the actions of IB-MECA on systemic hemodynamic parameters
including heart rate, mean arterial blood pressure, left ventricular (LV)
pressure, first derivative of LV pressure (LV dP/dt), and LAD
coronary artery blood flow in unpaced dogs. Bolus administration of IB-MECA
(100 µg/kg) had no effect on any systemic hemodynamic parameter measured
for at least 30 min (Fig. 2).
In contrast, an equivalent dose of the A1AR agonist
2-chloro-N6-cyclopentyladenosine (CCPA) caused shortlived
decreases in heart rate, LV systolic pressure, LV dP/dt, and mean
arterial blood pressure. CCPA also produced a marked increase in coronary
blood flow.
|
|
Ischemia-reperfusion data. A total of 33 dogs was initially included in the infarction study. One dog was excluded from the control group because of intractable ventricular fibrillation, and one dog was excluded from the group given IB-MECA at reperfusion because of high collateral blood flow. Thus a total of 31 dogs was included in the data analysis.
Hemodynamic and regional myocardial blood flow data are shown in Tables 1 and 2. There were no significant differences within or between groups throughout the experiment with regard to heart rate, mean arterial blood pressure, LV dP/dt, the rate-pressure product, or regional myocardial blood flow in either the nonischemic or ischemic regions, with the exception of a significant increase in mean arterial blood pressure at 3 h of reperfusion in the group of dogs treated with IB-MECA before occlusion. There were also no significant differences in blood pH, PO2, or PCO2 within and between groups at any of the times studied (data not shown).
|
|
Figure 3 summarizes the
effect of IB-MECA on infarct size. Myocardial infarct size expressed as a
percentage of the AAR was reduced significantly (40%, P <
0.05) in the two groups of dogs treated with IB-MECA (control = 25.2 ±
3.7%, IB-MECA before occlusion = 13.0 ± 3.2%, and IB-MECA during
reperfusion = 13.1 ± 3.9%). Myocardial infarct size expressed as a
percentage of the entire LV was also reduced significantly by IB-MECA (8.1
± 1.4%, 4.4 ± 1.4%, and 4.1 ± 1.2%, respectively.)
Remarkably, the reduction in infarct size was equivalent in magnitude in the
group of dogs treated with IB-MECA immediately before reperfusion compared
with the pretreated group. Pretreatment with IB-MECA did not reduce infarct
size in the group of dogs pretreated with glibenclamide (infarct size as a
percentage of the AAR = 20.6 ± 5.6% and as a percentage of the LV = 7.0
± 2.0%). Among the treatment groups, there were no significant
differences with respect to the LV weight (data not shown). Importantly, there
were also no differences among the groups with respect to the size of the AAR
(control = 32.0 ± 3.9%, IB-MECA before reperfusion = 32.1 ±
2.7%, IB-MECA before reperfusion = 31.4 ± 3.9 2.3%, and IB-MECA +
glibenclamide = 33.4 ± 2.3% of the LV).
|
Figure 3, B and C, illustrates the relationship between infarct size and transmural collateral blood flow measured at 30 min into the occlusion period in the four experimental groups. In control dogs, there was an inverse relationship between infarct size and collateral blood flow. This relationship was shifted downward in both of the IB-MECA-treated groups, indicating that the reduction in infarct size produced by IB-MECA occurred independently of changes in collateral blood flow. The relationship between infarct size and collateral flow was not shifted by IB-MECA in the group of dogs pretreated with glibenclamide.
|
DISCUSSION |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
We have recently focused on testing the efficacy of A3AR agonists in experimental models of ischemia-reperfusion injury (5, 21, 22, 41). The A3AR is the most recently identified subtype of adenosine receptor that is coupled to Gi/o inhibitory proteins similar to the A1AR (24). With the use of a chronically instrumented conscious rabbit model, we (5, 21) observed that pretreatment with IB-MECA (100 µg/kg) produced a significant protective effect against both reversible (myocardial "stunning") and irreversible injury (infarction). In these studies, IB-MECA was effective when administered intravenously at a dose that had no effect on heart rate or systemic blood pressure (5, 21). The protective effects of IB-MECA were blocked by the nonspecific adenosine receptor antagonist 8-sulfophenytheophylline but not by the A1AR antagonist N-0861, implying the involvement of the A3AR (5, 21). These results provided evidence that effective cardioprotection can be achieved after systemic administration of an A3AR agonist without causing unfavorable hemodynamic consequences.
The results of the present investigation using a dog model of
ischemia-reperfusion injury extend these previous observations. Similar to our
previous studies in the rabbit
(5,
21), we found that
pretreatment with IB-MECA effectively reduced infarct size from 25% of
the AAR in control dogs to 13% in dogs pretreated with 100 µg/kg of
IB-MECA (Fig. 3), a dose also
found to be hemodynamically inactive in the dog
(Fig. 2). The novel aspect of
the present study using the dog model is that we were able to provide more
detailed assessment of IB-MECA on hemodynamics and coronary artery blood flow.
Similar analyses have not been possible in previous studies conducted in
rodents. At a dose of 100 µg/kg, we found that IB-MECA did not influence
blood pressure, LV pressure, LV dP/dt, or the rate-pressure product
(Table 1 and
Fig. 2). In addition, IB-MECA
had no effect on coronary blood flow (Table
2 and Fig. 2). A
lack of effect of IB-MECA on hemodynamic parameters was apparent during the
ischemia-reperfusion studies as well as in preliminary studies in which the
effects of IB-MECA were observed for 30 min in control barbital-anesthetized
dogs. The lack of an effect of IB-MECA on coronary blood flow in these studies
is an important observation because it rules against the possibility that it
may cause coronary "steal," a complication that has been
demonstrated to occur with dipyridamole
(47). In addition, the lack of
hemodynamic effects suggests that IB-MECA was administered at a dose that did
not influence other AR subtypes in the heart or vasculature. By comparison, an
equivalent dose of the A1AR agonist CCPA reduced heart rate,
reduced systemic blood pressure, and increased coronary blood flow
(Fig. 2). Overall, these
results clearly suggest that the protective effects of IB-MECA are not
dependent on changes in the oxygen supply-demand balance. Rather, they suggest
that it acts via a direct cardioprotective mechanism. Previous studies
(9,
18,
19,
26,
33,
39,
40,
42–44)
using isolated hearts and isolated cardiomyocytes have suggested that
A3ARs are expressed in the myocardium and that they couple to
cardioprotective signaling mechanisms similar to those coupled to the
A1AR, presumably the KATP channel. We predict that
pretreatment with IB-MECA provided protection in our dog model by a comparable
mechanism. This theory is supported by the observation that the reduction in
infarct size provided by pretreating with IB-MECA was blocked completely by
glibenclamide. One interesting aspect of the present investigation is that
subendocardial blood flow was increased after 3 h of reperfusion in the
ischemia-reperfused myocardium in control animals
(Table 2). These data indicate
that hyperemia developed in the subendocardial region, which we believe is
related to the short period of ischemia utilized in our protocol. Importantly,
the distribution of blood flow across the myocardium in the
ischemia-reperfused region was identical in the two groups of dogs treated
with IB-MECA, indicating further that IB-MECA had no effect on blood flow at
the dose utilized in our investigation.
The second novel aspect of this work is that we found that IB-MECA was effective when administered at the time of reperfusion. In fact, we found that IB-MECA produced an equivalent reduction in infarct size whether it was administered 10 min before the onset of ischemia or administered 5 min before the release of the occlusion. These results suggest that, in addition to exerting favorable effects during ischemia, IB-MECA produced beneficial actions that attenuated reperfusion injury. We predict that there are two potential mechanisms by which IB-MECA may have reduced reperfusion injury. The first is via an anti-inflammatory mechanism. Jordan and colleagues (20) have previously observed, using an in vitro assay, that nanomolar concentrations of Cl-IB-MECA reduced the adhesion of neutrophils to coronary artery segments via actions on the endothelium rather than on the neutrophils. This effect of Cl-IB-MECA to reduce neutrophil adhesion was attributed to the A3AR, because the A3AR antagonist MRS-1220 (but not A1AR or A2AAR antagonists) antagonized its effects completely (20). These investigators (20) further demonstrated that treatment with Cl-IB-MECA reduced contractile dysfunction and neutrophil margination in an isolated rabbit heart model of neutrophil-mediated reperfusion injury. These observations, taken together with additional work by other investigators demonstrating that A3AR agonists reduce the expression of proinflammatory cytokines (35, 36) and reduce neutrophil function (7), provide additional support for the idea that IB-MECA reduced infarct size in the present investigation by an anti-inflammatory effect. A second complementary mechanism by which IB-MECA may have reduced infarct size, however, is by inhibiting apoptosis, because the A3AR is known to be capable of coupling to two well-known cell survival-signaling pathways including the phosphatidylinositol 3'-kinase/Akt kinase pathway (14, 37) and the Ras/Raf-1/MEK/ERK 1/2 pathway (37). This potential mechanism is supported by the results of Maddock and colleagues (27), who reported that Cl-IB-MECA reduced apoptosis of isolated rat cardiac myocytes subjected to simulated ischemia when administered during reoxygenation.
IB-MECA was originally shown to be 50-fold selective for rat
A3ARs vs. rat A1ARs and A2AARs
(13). With the use of canine
adenosine receptors expressed in HEK-293 cells, we have also found in the
present investigation that IB-MECA is 50-fold more potent at binding to
the canine A3AR versus the canine A1AR
(Fig. 1). These binding data
coupled with the observation that IB-MECA was hemodynamically inactive in our
in vivo studies suggest that the A3AR was the primary site of
IB-MECA to reduce infarct size. It should be noted, however, that Linden's
group (31) has recently
provided evidence that A3AR agonists including Cl-IB-MECA may bind
to A2AARs with higher affinity than originally appreciated.
Furthermore, this group has suggested
(25) that A2AAR
agonists are effective anti-inflammatory/tissue-protective agents at low,
nonhypotensive doses due to efficient coupling of A2AARs in immune
cells. It remains possible, therefore, that IB-MECA was effective in the
present investigation via an anti-inflammatory effect mediated via the
A2AAR or via a combined effect mediated through A2AARs
and A3ARs. The large size of the dog precludes the use of selective
antagonists to verify the involvement of individual AR subtypes in the present
investigation. In preliminary studies
(15), however, we observed
that Cl-IB-MECA does not reduce infarct size in mice lacking A3ARs
(A3AR gene "knockout" mice), supporting a role for
these agents acting to modulate ischemia-reperfusion injury by interacting
with the A3AR.
The effect of A3AR agonists on hemodynamics differs among species. Although we (11, 17, 45) have observed that IB-MECA (and Cl-IB-MECA) has no hemodynamic effects in rabbits and dogs, Cl-IB-MECA and N6-(3-aminophenylethyl)adenosine have been reported to cause a short-lived hypotension without any change in heart rate in rats and mice. The hypotensive actions of A3AR agonists in rodents is likely an effect mediated via the release of vasoactive mediators from mast cells because 1) a concomitant increase in plasma histamine levels occurs in rodents [but not in rabbits (5)] in response to A3AR agonists (11, 45); 2) stimulatory A3ARs have been identified on rodent mast cells (34); and 3) the hypotensive actions of A3AR agonists are antagonized by mast cell stablizers, including sodium cromoglycate and lodoxamide (17). We have previously demonstrated that A2BARs rather than the A3AR modulate degranulation of canine mast cells (3). Feoktistov and Biaggioni (10) have demonstrated that A2BARs regulate human mast cell functions. Hence, differences in the adenosine receptors that regulate mast cells may underlie the variable hemodynamic actions of A3AR agonists observed between rodents and other mammalian species.
In conclusion, we demonstrated in a large animal model that the A3AR agonist IB-MECA effectively reduces infarct size when given before ischemia or when given during reperfusion. The protective actions of IB-MECA occurred without altering systemic hemodynamics or coronary blood flow. These results suggest that A3AR agonists may be useful cardioprotective agents for the treatment of acute myocardial ischemia-reperfusion injury.
|
DISCLOSURE |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|
REFERENCES |
|---|
|
TOPABSTRACTMETHODSRESULTSDISCUSSIONDISCLOSUREREFERENCES |
|---|
4. Mol
Pharmacol 61:
455–462, 2002.
expression by adenosine: role of A3 adenosine
receptors. J Immunol 156:
3435–3442, 1996.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zheng, R. Wang, E. Zambraski, D. Wu, K. A. Jacobson, and B. T. Liang Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3685 - H3691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-S. Park, H. Zhao, Y. Jang, R. A. Mueller, and Z. Xu N6-(3-Iodobenzyl)-adenosine-5'-N-methylcarboxamide Confers Cardioprotection at Reperfusion by Inhibiting Mitochondrial Permeability Transition Pore Opening via Glycogen Synthase Kinase 3beta J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 124 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Gross and G. J. Gross Ligand triggers of classical preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 212 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kin, A. J. Zatta, M. T. Lofye, B. S. Amerson, M. E. Halkos, F. Kerendi, Z.-Q. Zhao, R. A. Guyton, J. P. Headrick, and J. Vinten-Johansen Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine Cardiovasc Res, July 1, 2005; 67(1): 124 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. T. Gan, V. Rajapurohitam, J. V. Haist, P. Chidiac, M. A. Cook, and M. Karmazyn Inhibition of Phenylephrine-Induced Cardiomyocyte Hypertrophy by Activation of Multiple Adenosine Receptor Subtypes J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 27 - 34. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
